These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 3069436)

  • 1. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia.
    Henwood JM; Heel RC
    Drugs; 1988 Oct; 36(4):429-54. PubMed ID: 3069436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lovastatin: a new cholesterol-lowering agent.
    McKenney JM
    Clin Pharm; 1988 Jan; 7(1):21-36. PubMed ID: 3278832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
    Lea AP; McTavish D
    Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
    Todd PA; Goa KL
    Drugs; 1990 Oct; 40(4):583-607. PubMed ID: 2083515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia.
    Gholami K; Tavakoli N; Maleki M; Shafiee A
    J Clin Pharm Ther; 1998 Jun; 23(3):213-21. PubMed ID: 9831973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia.
    Vega GL; Grundy SM
    J Intern Med; 1991 Oct; 230(4):341-50. PubMed ID: 1919427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lovastatin: a new cholesterol-lowering agent.
    Krukemyer JJ; Talbert RL
    Pharmacotherapy; 1987; 7(6):198-210. PubMed ID: 3328165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin.
    Gullestad L; Nordal KP; Forfang K; Ihlen H; Høstmark A; Berg KJ; Cheng H; Schwartz MS; Geiran O; Simonsen S
    J Intern Med; 1997 Dec; 242(6):483-90. PubMed ID: 9437409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lovastatin extended release: a review of its use in the management of hypercholesterolaemia.
    Curran MP; Goa KL
    Drugs; 2003; 63(7):685-99. PubMed ID: 12656649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of primary mixed hyperlipidemia with lovastatin.
    Vega GL; Grundy SM
    Arch Intern Med; 1990 Jun; 150(6):1313-9. PubMed ID: 2353864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
    Garg A; Grundy SM
    N Engl J Med; 1988 Jan; 318(2):81-6. PubMed ID: 3422105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia.
    Cortner JA; Bennett MJ; Le NA; Coates PM
    J Inherit Metab Dis; 1993; 16(1):127-34. PubMed ID: 8487493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Personal experience with lovastatin, a HMG-CoA reductase inhibitor (Mevacor, MSD) in the treatment of hypercholesterolemia].
    Vaverková H; Skottová N; Pudilová L; Horcicka V; Jezdinský J; Trtková M
    Vnitr Lek; 1991 May; 37(5):463-9. PubMed ID: 1842144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
    Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias].
    Bertolami MC; Martinez TL; Faludi AA; Pinto LE; Melo RS; Bismarck ZF; Batlouni M
    Arq Bras Cardiol; 1991 May; 56(5):407-12. PubMed ID: 1823741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.